Depression Drug Failure Sets Eli Lilly Back
Insights - Eli Lilly and Company (LLY) on Thursday said it would not seek approval for edivoxetine, an experimental drug to treat major depression, after it failed … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Levin’s Legacy: Teva’s Alternative Development Program
Research - CEO Jeremy Levin may be gone from Teva (TEVA), but it’s clear that while his tenure was short, his legacy may be meaningful. The challenge … Continue Reading
Read now
Lexicon’s Pipeline Continues to Struggle
Insights - Lexicon Pharmaceuticals (LXRX) announced the latest in a string of disappointments for its development pipeline, but management remains upbeat. On December 3, 2013, the company … Continue Reading
Read now
OncoMed Shares Soar on Celgene Agreement
Insights - OncoMed (OMED) rose nearly 100% to $27.70 per share on December 3, 2013, when it announced that an agreement with Celgene (CELG) to co-develop and … Continue Reading
Read now
BioDelivery Sciences: Delivering Profits in 2014
Research - In the biotechnology sector, innovation can come in one of a few forms, including novel drugs or novel ways to deliver existing drugs. BioDelivery Sciences … Continue Reading
Premium
Baxter and Halozyme resubmit HyQvia to FDA
Insights - If at first you don’t succeed, try again. Baxter Healthcare (BAX) and Halozyme Therapeutics, Inc. (HALO) submitted an amended biologics license application (BLA) to the … Continue Reading
Read now
Idenix Sues Gilead for Hep-C Patent Infringement
Insights - The turf battle for the lucrative Hepatitis-C market is heating up, not only on the clinical front but also in the courts. Idenix Pharmaceuticals, Inc. … Continue Reading
Read now